Capricor Therapeutics (CAPR) Lowered to “Hold” at Zacks Investment Research

Capricor Therapeutics (NASDAQ:CAPR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.60 price target (up from $6.50) on shares of Capricor Therapeutics in a research report on Friday, January 26th.

Shares of Capricor Therapeutics (NASDAQ CAPR) traded up $0.09 during trading hours on Wednesday, hitting $2.04. 1,949,071 shares of the company were exchanged, compared to its average volume of 639,203. The firm has a market cap of $52.45, a P/E ratio of -3.09 and a beta of -4.66. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25.

Several large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN acquired a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $107,000. Jane Street Group LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $190,000. Belpointe Asset Management LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $249,000. Virtu KCG Holdings LLC raised its holdings in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock worth $149,000 after buying an additional 152,614 shares during the period. Finally, Brown Advisory Inc. acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $1,796,000. Institutional investors and hedge funds own 4.05% of the company’s stock.

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/14/capricor-therapeutics-capr-lowered-to-hold-at-zacks-investment-research.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply